Nicholas Latimer BSc, MSc, PhD
Reader in Health Economics
University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA
Tel: (+44) (0)114 222 0821
Fax: (+44) (0)114 222 0749
I joined ScHARR in June 2008. Before this I graduated with a degree in economics from the University of Nottingham in 2003 and an MSc in Health Economics from the University of York in 2004. I have experience in both the public and the private sectors. I have previously worked as a Research Officer and Analyst at NERA Economic Consulting, a Health Economics Fellow at Queen Mary, University of London (QMUL), and a Health Economist at Roche Products Ltd. While at QMUL I was the principal health economist on the NICE clinical guideline for osteoarthritis.
Since joining ScHARR I have worked on several clinical trials, NICE Technology Appraisals and Public Health guidelines, and consultancy projects. Much of my work focuses on the incorporation of survival analysis in economic evaluations and in 2009 I was awarded an NIHR Doctoral Research Fellowship on this topic, which I completed in 2012. In 2015 I was awarded an NIHR Post-doctoral Research Fellowship which continued this work. In 2019 I began a Senior Research Fellowship funded by Yorkshire Cancer Research in which I will continue my work on treatment switching adjustment methods but will also focus on the application of causal inference techniques to estimate comparative effectiveness from cancer registry datasets. I have led a number of research and consultancy projects, primarily focusing upon adjusting survival estimates in the presence of treatment switching in clinical trials. I have authored NICE Decision Support Unit technical support documents on survival analysis (TSD14, 2011) and on treatment switching (TSD16, 2014)
My research interests focus on economic evaluation methodology, with a particular emphasis on the incorporation of survival analysis within economic models. My doctoral research fellowship was focused primarily on methods for adjusting survival estimates in the presence of treatment switching - that is, when patients in the control group of a clinical trial switch onto the experimental treatment, thus confounding estimates of the treatment effect (where the relevant question for an economic analysis is what would have happened if control group patients did not receive this experimental treatment).
I also have an active interest in economic evaluations alongside clinical trials, and particularly the incorporation of value of information analysis in feasibility trials.
My teaching interests lie in the field of health economics, economic evaluation and survival analysis. I have previously co-ordinated a module on Economic Evaluation on the Health Economics and Decision Modelling MSc, and I teach Survival Analysis on the Health Services Research Methods module for Economics and Health Economics MSc students, and on the Modelling module for International Health Technology Assessment MSc students. I have completed the Certificate in Learning and Teaching (PGCertHE), the University Of Sheffield's professional development course in learning and teaching in higher education.
I am currently supervising two PhD students. Abu Alshreef is investigating adjustment for non-adherence in economic evaluation, and Rachid Rafia is exploring multi-state models and partitioned survival models for cancer treatments. I am interested in supervising potential students on topics around adjustment for treatment switching in clinical trials, and the use of causal inference methods to estimate comparative effectiveness from observational datasets.
In 2012 I completed an NIHR Doctoral Research Fellowship. I developed a methodological and applied study of the role and value of alternative methods for incorporating survival analysis into economic evaluations of metastatic oncology treatments to inform clinical policy and resource allocation decisions. My current NIHR Post-doctoral fellowship is continuing with this work.
- I am a member of NICE Technology Appraisal Committee B
- I have been a member of the Yorkshire and Humber Research for Patient benefit Programme Regional Advisory committee.
- I am a member of the Health Economists Study Group.
- I am a Fellow of the Higher Education Academy.
- I have been an invited expert for the NICE Scientific Advice Programme.
- Yorkshire Cancer Research Senior Research Fellowship
- Various other applied projects conducting analysis to adjust for treatment switching in clinical trials.
- Clinical and cost effectiveness of aphasia computer therapy compared with usual stimulation long term post stroke (Big CACTUS) (NIHR/HTA)
- Behavioural activation therapy for treating post-stroke depression: a feasibility randomised controlled trial (BEADS) (NIHR/HTA)
- Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A & Sharples L (2017) Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods. Medical Decision Making, 37(4), 377-390. View this article in WRRO
- Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2017) Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method. Statistical Methods in Medical Research, 26(2), 724-751.
- Latimer NR, Abrams KR, Amonkar MM, Stapelkamp C & Swann RS (2015) Adjusting for the Confounding Effects of Treatment Switching—The BREAK-3 Trial: Dabrafenib Versus Dacarbazine. The Oncologist, 20(7), 798-805.
- Latimer NR (2015) Treatment switching in oncology trials and the acceptability of adjustment methods. Expert Review of Pharmacoeconomics & Outcomes Research, 15(4), 561-564.
- Latimer NR, Carroll C, Wong R, Tappenden P, Venning MC & Luqmani R (2014) Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal. PharmacoEconomics, 32(12), 1171-1183. View this article in WRRO
- Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2014) Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.. Med Decis Making, 34(3), 387-402.
- Watkins C, Huang X, Latimer N, Tang Y & Wright EJ (2013) Adjusting overall survival for treatment switches: Commonly used methods and practical application. Pharmaceutical Statistics, 12(6), 348-357.
- Collins M & Latimer N (2013) NICE's end of life decision making scheme: impact on population health.. BMJ, 346, f1363.
- Latimer NR (2013) Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.. Med Decis Making, 33(6), 743-754.
- Morden JP, Lambert PC, Latimer N, Abrams KR & Wailoo AJ (2011) Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.. BMC Med Res Methodol, 11, 4. View this article in WRRO
- Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG & National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group (2009) Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.. BMJ, 339, b2538.